Sermorelin, also known as GRF 1-29 (Growth Hormone-Releasing Factor 1-29), is a synthetic peptide comprising the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH). As the shortest fully bioactive fragment of GHRH, Sermorelin retains the complete receptor-binding domain responsible for stimulating growth hormone (GH) secretion from the anterior pituitary gland.
In research settings, Sermorelin acts as a GHRH receptor agonist, binding to pituitary somatotrophs and triggering pulsatile GH release in a manner that closely mimics physiological secretion patterns. This has made it a valuable tool in studies exploring the hypothalamic-pituitary axis, age-related GH decline, and neuroendocrine signalling.
Researchers have investigated Sermorelin in the context of somatotropic axis function, body composition modelling, bone density studies, and metabolic research. Its relatively short half-life and mechanism of action through endogenous pathways make it a subject of interest compared to exogenous GH administration models.
Storage: Store at -20°C. Protect from light and moisture. Reconstitute with bacteriostatic water prior to use in research applications.
Molecular Formula
C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight
3357.9 g/mol
Purity
>98%
CAS Number
86168-78-7
Form
Lyophilised Powder
Research Applications
Neuroendocrine signalling research, Hypothalamic-pituitary axis studies, Somatotropic function modelling, Age-related GH decline research, Metabolic and body composition studies, Bone density research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.